Abstract
Objectives. Data available so far has shown a hemodynamic stabilisation and improved lactate clearance for a new high-adsorption membrane oXiris® filter. However, the evidence-based use of oXiris® for sepsis is still limited. This study aims to explore the clinical effect of hemadsorption with oXiris® filter in septic
shock patients.
Materials and Methods. Adult septic shock patients treated with at least one oXiris® set during 2022 were retrospectively analyzed. Those with known chronic kidney failure were excluded. The demographic, clinical, laboratory and survival data were collected from patient’s files.
Results. The median age was 65 [IQR 47–73] years. Twenty-one (60%) patients had at least one comorbidity upon hospitalization, predominated by cardiovascular disease in 13 (37%) patients and diabetes in 11 (31%) patients. The median pre-treatment Sequential Organ Failure Assessment (SOFA) Score points were 12 [IQR 10–33]. High vasoactive drug dose (median 0.27 μg/kg/min [IQR 0.13–0.39] and high inflammatory markers (Procalcitonin (PCT); median 26 ng/mL [IQR 11–71] were main indications for initiation of hemadsorption. Abdominal infection [n = 13] was the most common source of sepsis. Gram-negative sepsis was found in 25 (71.4%) patients. The median oXiris® hemofilter initiation treatment time was 19 h [IQR14–48]. After one oXiris® set, median vasoactive drug dose, blood lactate, PCT levels and SOFA score points decreased by 0.06 μg/kg/min (25%), 0.5 mmol/L (21%), 9.7 ng/mL (37.3%) and 1 point (8.3%) respectively. Twenty-eight-day mortality was 45.7% [n = 16]. In logistic regression analysis only SOFA scale and oXiris® hemofilter treatment initiation time were considered as independent risk factors for 28-day mortality (p < 0.001).
Conclusions. Hemadsorption with oXiris® reduce the use of vasoactive drugs, lactate level and SOFA score in septic shock patients. Shorter oXiris® hemofilter treatment initiation time could be potentially
associated with better outcome.
shock patients.
Materials and Methods. Adult septic shock patients treated with at least one oXiris® set during 2022 were retrospectively analyzed. Those with known chronic kidney failure were excluded. The demographic, clinical, laboratory and survival data were collected from patient’s files.
Results. The median age was 65 [IQR 47–73] years. Twenty-one (60%) patients had at least one comorbidity upon hospitalization, predominated by cardiovascular disease in 13 (37%) patients and diabetes in 11 (31%) patients. The median pre-treatment Sequential Organ Failure Assessment (SOFA) Score points were 12 [IQR 10–33]. High vasoactive drug dose (median 0.27 μg/kg/min [IQR 0.13–0.39] and high inflammatory markers (Procalcitonin (PCT); median 26 ng/mL [IQR 11–71] were main indications for initiation of hemadsorption. Abdominal infection [n = 13] was the most common source of sepsis. Gram-negative sepsis was found in 25 (71.4%) patients. The median oXiris® hemofilter initiation treatment time was 19 h [IQR14–48]. After one oXiris® set, median vasoactive drug dose, blood lactate, PCT levels and SOFA score points decreased by 0.06 μg/kg/min (25%), 0.5 mmol/L (21%), 9.7 ng/mL (37.3%) and 1 point (8.3%) respectively. Twenty-eight-day mortality was 45.7% [n = 16]. In logistic regression analysis only SOFA scale and oXiris® hemofilter treatment initiation time were considered as independent risk factors for 28-day mortality (p < 0.001).
Conclusions. Hemadsorption with oXiris® reduce the use of vasoactive drugs, lactate level and SOFA score in septic shock patients. Shorter oXiris® hemofilter treatment initiation time could be potentially
associated with better outcome.
| Original language | English |
|---|---|
| Pages (from-to) | 6 |
| Number of pages | 1 |
| Journal | Medicina (Kaunas) |
| Volume | 59 |
| Issue number | Suppl.2 |
| Publication status | Published - 2023 |
| Event | RSU Research Week 2023: Research Week 2023 Rīga Stradiņš University - Riga Stradins University, Riga, Latvia Duration: 27 Mar 2023 → 31 Mar 2023 https://rw2023.rsu.lv/general-information https://rw2023.rsu.lv |
Field of Science*
- 3.2 Clinical medicine
Publication Type*
- 3.4. Other publications in conference proceedings (including local)
